Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate

Journal of Pharmacological Sciences

Volumn 115, Issue 3, 2011, Pages 374-382

  Ogoda, Masaki ^a   Niiya, Ryo ^a   Koshika, Tadatsura ^b   Yamada, Shizuo ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Chronic obstructive pulmonary disease; Ex vivo lung muscarinic receptor binding; Glycopyrrolate; Ipratropium; Tiotropium

Indexed keywords

GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR; SCOPOLAMINE; TIOTROPIUM BROMIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BLADDER MUCOSA; BREATHING MUSCLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; IN VITRO STUDY; LUNG PARENCHYMA; MALE; MUSCLE CONTRACTILITY; NONHUMAN; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SUBMANDIBULAR GLAND;

EID: 79952812951     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10311FP     Document Type: Article

References (39)

1. Barnes PJ. Neural control of human airways in health and disease. Am Rev Respir Dis. 1986;134:1289-1314. (Pubitemid 17216914)
2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverly P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-575.
3. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstructive due to emphysema. N Engl J Med. 1984;311:421-425. (Pubitemid 14058252)
4. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res. 2006;7:73.
5. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Kordecki L, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216. (Pubitemid 34162819)
6. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
7. Casaburi R. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809-817. (Pubitemid 40775509)
8. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Inter Med. 2005;143:317-326.
9. Cramer JA, Bradey-Kennedy C, Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007;14:25-29. (Pubitemid 46637657)
10. Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drug. 2010;19:257-264.
11. Josep LH. Tiotropium bromide: an updata. Open Respir Med J. 2009;3:43-52.
12. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R. Tiotropium (Spiriva): mechanistical consideraions and clinical profile in obstructive lung disease. Life Sci. 1999;64:457-464. (Pubitemid 29066693)
13. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med. 1991;91:28S-32S.
14. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al, editors, Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 141-160.
15. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996;110:62-70.
16. Walker IV, Kaiser FB, Kowal DL, Suratt PM. Prolonged effect of inhaled glycopyrrolate in asthma. Chest. 1987;91:49-51. (Pubitemid 17215791)
17. Schroeckenstein DC, Bush RK, Chervinsky P, Busse WW. Twelve-hour bronchodilation in asthma with a single aerosol dose of the anticholinergic compound glycopyrrolate. J Allergy Clin Immunol. 1988;82:115-119.
18. Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J. 1996;9:100-103. (Pubitemid 26037532)
19. Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127:413-420. (Pubitemid 29245679)
20. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther. 2005;27:377-392. (Pubitemid 40732646)
21. Yoshida A, Fujino T, Maruyama S, Ito Y, Taki Y, Yamada S. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: Bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder. J Pharmacol Sci. 2010;112:142-150.
22. 35S] GTPγS in rat brain and spinal cord. Br J Pharmacol. 2003;139:1462-1468.
23. Ohmori Y, Onoue S, Endo K, Matsumoto A, Uchida S, Yamada S. Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. Life Sci. 2006;79:138-143. (Pubitemid 43737060)
24. Oki T, Kimura R, Saito M, Miyagawa I, Yamada S. Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004;172:2059-2064. (Pubitemid 39363128)
25. Oki T, Sato S, Miyata K, Yamada S. Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice. Br J Pharmacol. 2005;145:219-227. (Pubitemid 40756526)
26. Oki T, Toma-Okura A, Yamada S. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther. 2006;316:1137-1145. (Pubitemid 43345287)
27. Maruyama S, Tsukada H, Nishiyama S, Kakiuchi T, Fukumoto D, Oku N, et al. In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther. 2008; 325:774-781.
28. 3H]WB4101: effect of 6-hydroxydomine treatment. J Pharmacol Exp Ther. 1980; 215:176-185
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 93:265-275.
30. Giraldo E, Martos F, Gomeza A, Garcia A, Vigano MA, Ladinsky H, et al. Characterization of muscarinic receptor subtypes in human tissues. Life Sci. 1988;43:1507-1515.
31. Caulfield MP. Muscarinic receptor: characterization, coupling and function. Pharmacol Ther. 1993;58:319-379. (Pubitemid 23273186)
32. Eglen RM, Reddy H, Watson N, Vhallis RAJ. Muscarinic acetylcholine receptors in smooth muscles. Trends Pharmacol Sci. 1994;15:114-115.
33. 2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol. 1996;153:73-82.
34. Belmonte KE. Cholinergic pathways in the lungs and anticholin ergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:297-304. (Pubitemid 41566939)
35. Ito Y, Oyunzul L, Seki M, Fujino T, Matsui M, Yamada S. Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 single subtype knockout mice. Br J Pharmacol. 2009;156:1147-1153.
36. Villeti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guineapig and human airways. Br J Pharmacol. 2006;148:291-298. (Pubitemid 43801176)
37. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther. 2009;330:660-668.
38. Dowling MR, Charlton SJ. Quantifying the association and dissociation rates of unlabelled antagonists at the muscarnic M3 receptors. Br J Pharmacol. 2006;148:927-937. (Pubitemid 44543610)
39. Armstrong SR, Briones S, Horger B, Richardson CL, Jaw-Tsai S, Hegde SS. Pharmacological analysis of the interaction of antimuscarinic drugs at M(2) and M(3) muscarinic receptors in vivo using the pithed rat assay. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:341-349.